Multiple Antioxidants in the Prevention and Treatment of Parkinson’s Disease

Journal of the American College of Nutrition

Volumn 18, Issue 5, 1999, Pages 413-423

  Prasad, Kedar N ^a   Cole, William C ^a   Kumar, Bipin ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antioxidants; Neurodegeneration; Oxidative stress; Parkinson s disease; Prevention

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHROMIUM; LEVODOPA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SELEGILINE; SELENIUM; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; DIET SUPPLEMENTATION; EXPOSURE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK POPULATION; HUMAN; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; HUMANS; MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; SELEGILINE; VITAMINS;

EID: 0032848686     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.1999.10718878     Document Type: Article

References (102)

1. Olanow CW: “Neurodegeneration and Neuroprotection in Parkinson's Disease.” New York: Academic Press, 1996.
2. Moghal S, Rajput AH, D'Arcy C, Rajput R: Prevalence of movement disorders in elderly community residents. Neuroepidemiology 13: 175-178, 1994.
3. Mena I, Horiuchi K, Burke K, Cotzia GC: Chronic manganese poisoning. Individual susceptibility and absorbtion of iron. Neurology 19: 1000-1006, 1969.
4. Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35: 949-956, 1985.
5. Langston J: Epidemiology versus genetics in Parkinson's disease: Progress in resolving an age-old debate. Ann of Neurol 44: 545-552, 1998.
6. Golbe LI, Farrell T, Davis PH: Case-control survey of early life dietary factors in Parkinson's disease. Arch Neurol 45: 1350-1353, 1988.
7. Seidler A, Hellenbrand W, Robra B-P, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E: Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46: 1275-1284, 1996.
8. Zhang Z-X, Anderson D, Lavine L, Mantel N: Patterns of acquiring parkinsonism-dementia complex on Guam. 1944 through Arch Neurol 47: 1019-1024, 1990.
9. de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, Hofman A: Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54: 762-765, 1997.
10. Le Couteur DG, Leighton PW, McCann SJ, Pond S: Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Movement Disord 12: 760-763, 1997.
11. Yamamoto M, Kondo I, Ogawa N, Asanuma M, Yamashita Y, Mizuno Y: Genetic association between susceptibility to Parkinson's disease and alpha1-antichymotrypsin polymorphism. Brain Res 759: 153-155, 1997.
12. Costa P, Checkoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD, Costa LG: Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Genetics 74: 154-156, 1997.
13. Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I: Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease. J of Neural Transm-Gen Section 103: 843-849, 1996.
14. Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997.
15. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T: Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sciences USA 90: 11282-11286, 1993.
16. Zhou W, Hurlbert M, Schaack J, Prasad K, Freed C: Overexpression of human a-synuclein increases dopamine neuron sensitivity to 6-hydroxydopamine. J Neurosci. submitted.
17. Chen P, Jiang X, Forna L, Dimonte D, Tanner C, Langston J: Absence of mutation in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. In Press.
18. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608, 1998.
19. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695, 1993.
20. Parker WD, Jr., Swerdlow RH: Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genetics 62: 758-762, 1998.
21. Cooper JM, Schapira AH: Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr 29: 175-183, 1997.
22. Bowling A, Beal M: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56: 1151-1171, 1995.
23. Mann V, Cooper J, Krige D, Daniel S, Shapira A, Marsden C: Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115: 333-342, 1992.
24. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD: Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2: 1219-1220, 1987.
25. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA: Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease [published erratum appears in Neurology 45: 1420, 1995. Neurology 45: 1138-1143, 1995.
26. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520, 1989.
27. Perry TL, Godin DV, Hansen S: Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310, 1982.
28. Sofic E, Lange KW, Jellinger K, Riederer P: Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-230, 1992.
29. Ambani LM, Van Woert MH, Murphy S: Brain peroxidase and catalase in Parkinson disease. Arch Neurol 32: 114-118, 1975.
30. Kish SJ, Morito C, Hornykiewicz O: Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343-346, 1985.
31. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.
32. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD: Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study [published erratum appears in Mov Disord 9: 380, Movement Disord 9: 92-97, 1994.
33. Sanchez-Ramos J, Overvik E, Ames B: A marker of oxyradicalmediated DNA damage (8-hydroxy-29-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3: 197-204, 1994.
34. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183, 1993.
35. Fahns A: High-dosage antioxidants in early Parkinson's disease. Arch Neurol 45: 810a, 1988.
36. Smith TS, Parker Jr, WD, Bennett Jr JP: L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5: 1009-1011, 1994.
37. Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A: Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 171: 55-58, 1994.
38. Spencer JP, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B: Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353: 246-250, 1994.
39. Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643, 1978.
40. Sax DS, Tarsy D: Side-effects of L-dopa. N Eng J Med 285: 1033-1037, 1971.
41. Pentland B, Matthews D, Mawdsley C: Parkinson's disease: Long-term results of levodopa therapy. Scott Med J 27: 284-287, 1982.
42. Kaye JA, Feldman RG: The role of L-dopa holiday in the longterm management of Parkinson's disease. Clin Neuropharmacol 9: 1-13, 1986.
43. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J: The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann of Neurol 38: 771-777, 1995.
44. Mytilineou C, Radcliffe PM, Olanow CW: L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J of Neurochem 68: 434-436, 1997.
45. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann of Neurol 39: 29-36, 1996.
46. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann of Neurol 39: 37-45, 1996.
47. Fearnley JM, Lees AJ: Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301, 1991.
48. Lang AE, Lozano AM: Parkinson's disease. First of two parts. N Eng J Med 339: 1044-1053, 1998.
49. Lang AE, Lozano AM: Parkinson's disease. Second of two parts. N Eng J Med 339: 1130-1043, 1998.
50. Martin J: Molecular basis of the neurodegenerative disorders. N Eng J Med 340: 1970-1980, 1999.
51. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527-605, 1979.
52. Ames B, Shigenaga M, Hagan T: Oxidants, antioxidants, and the degenerative disease of aging. Proc Natl Acad Sci USA 90: 7915-7922, 1993.
53. Chan PH, Fishman RA: Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. J Neurochem 35: 1004-1007, 1980.
54. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624, 1990.
55. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J: NMDAdependent superoxide production and neurotoxicity. Nature 364: 535-537, 1993.
56. Kiyosawa H, Suko M, Okudaira H, Murata K, Miyamoto T, Chung MH, Kasai H, Nishimura S: Cigarette smoking induces formation of 8-hydroxydeoxyguanosine, one of the oxidative DNA damages in human peripheral leukocytes. Free Rad Res Commun 11: 23-27, 1990.
57. Reznick AZ, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B: Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem J 286: 607-611, 1992.
58. Schectman G, Byrd JC, Hoffmann R: Ascorbic acid requirements for smokers: analysis of a population survey. Am J Clin Nutr 53: 1466-1470, 1991.
59. Duthie GG, Arthur JR, James WP: Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 53: 1061S-1063S, 1991.
60. Winterbourn CC: Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett 82-83: 969-974, 1995.
61. Ames BN, Profet M, Gold LS: Dietary pesticides (99.99% all natural). Proc Natl Acad Sci USA 87: 7777-7781, 1990.
62. Gold LS, Slone TH, Stern BR, Manley NB, Ames BN: Rodent carcinogens: setting priorities. Science 258: 261-265, 1992.
63. Guyton A: “Blood Flow through Special Areas of the Body. Textbook of Medical Physiology.” 4th ed. Philadelphia: W.B. Saunders, pp 367-378, 1971.
64. Boveris A, Chance B: The mitochondrial generation of hydrogen peroxide: general properties and the effect of hyperbaric oxygen. Biochem J 134: 707-716, 1973.
65. Marttila RJ, Lorentz H, Rinne UK: Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321-331, 1988.
66. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692-697, 1989.
67. Dexter D, Jenner P, Schapira A, Marsden C: Alterations in levels of iron, ferritin and other trace metals in neurodegenerative diseases affecting basal ganglia. Ann Neurol 32: S94-S100, 1992.
68. Bondy SC: The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 208: 337-345, 1995.
69. Ebadi M, Srinivasan SK, Baxi MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 48: 1-19, 1996.
70. Halliwell B: Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Sup 126: 23-33, 1989.
71. Olanow CW: Oxidation reactions in Parkinson's disease. Neurology 40: Sup 32-37; Disc 37-39, 1990.
72. Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG: Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 51: 621-623, 1988.
73. Pillai SR, Traber MG, Steiss JE, Kayden HJ, Cox NR: Alphatocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids 28: 1101-1105, 1993.
74. Cadet JL, Katz M, Jackson-Lewis V, Fahn S: Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10-15, 1989.
75. Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, Carvey PM: Alpha tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: Dose response study and correlation with plasma levels. Neurology 47: 1037-1042, 1996.
76. Vatassery GT, Fahn S, Kuskowski MA: Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 50: 1900-1902, 1998.
77. Krinsky N: Antioxidant functions of carotenoids. Free Radical Biol Med 7: 617-635, 1989.
78. Zhang LX, Cooney RV, Bertram JS: Carotenoids up-regulate connexin-43 gene expression independent of their provitamin A or antioxidant properties. Cancer Res 52: 5707-5712, 1992.
79. Hazuka M, Edwards-Prasad J, Newman F, Kinzie JJ, Prasad KN: Beta-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 9: 143-149, 1990.
80. Meyskens Jr FL: Role of vitamin A and its derivatives in thetreatment of human cancer. In Prasad KN, Santamaria L, Williams RM (eds). “Nutrients in Cancer Prevention and Treatment.” Totowa, New Jersey: Humana Press, pp 349-362, 1995.
81. Carter CA, Pogribny M, Davidson A, Jackson CD, McGarrity LJ, Morris SM: Effects of retinoic acid on cell differentiation and reversion towards normal in human endometrial adenocarcinoma (RL95-2) cells. Anticancer Res 16: 17-24, 1996.
82. Vile GF, Winterbourn CC: Inhibition of adriamycin promoted microsomal lipid peroxidation by b-carotene, a-tocopherol and retinal at high and low oxygen partial pressure. FEBS Lett 238: 353-356, 1988.
83. McCay PB: Vitamin E: Interactions with free radicals and ascorbate. Ann Rev Nutr 5: 323-340, 1985.
84. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp D, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAFI/CIPI via C/EBPb. Nat Med 3: 1233-1241, 1997.
85. Ingold KU, Burton GW, Foster DO, Hughes L, Lindsay DA, Webb A: Biokinetics of and discrimination between dietary RRRand SRR-alpha-tocopherols in the male rat. Lipids 22: 163-172, 1987.
86. Prasad K, Edwards-Prasad J: Vitamin E and cancer prevention: Recent advances and future potentials. J Am Coll Nutr 11: 487-500, 1992.
87. Prasad K, Edwards-Prasad J: Effect of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 42: 550-555, 1982.
88. Schwartz JL: Molecular and biochemical control of tumor growth following treatment with carotenoids or tocopherols. In: Prasad KN, Santamaria L, Williams RM (eds). “Nutrients in Cancer Prevention and Treatment.” New Jersey: Humana Press, pp 287-316, 1995.
89. Helson L, Verma M, Helson C: Vitamin E and human neuroblastoma. In: Meyskens Jr F, Prasad K (eds). “Modulation and Mediation of Cancer Cells by Vitamins.” Basel: Karger, pp 258-265, 1983.
90. Witschi A, Reddy S, Stofer B, Lauterburg BH: The systemic availability of oral glutathione. Eur J Clin Pharmacol 43: 667-669, 1992.
91. Niki E: Mechanisms and dynamics of antioxidant action of ubiquinol. Mol Asp Med 18: S63-S70, 1997.
92. Niki E: Interaction of ascorbate and a-tocopherol. Ann N York Acad Sci 498: 186-199, 1987.
93. Stoyanovsky DA, Osipov AN, Quinn PJ, Kagan VE: Ubiquinonedependent recycling of vitamin E radicals by superoxide. Arch Biochem Biophy 323: 343-351, 1995.
94. Hiramatsu M, Velasco RD, Wilson DS, Packer L: Ubiquinone protects against loss of tocopherol in rat liver microsomes and mitochondrial membranes. Res Commun Chem Pathol Pharmacol 72: 231-241, 1991.
95. Chen RS, Huang CC, Chu NS: Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 37: 212-218, 1997.
96. Birkmayer W, Birkmayer J, Vrecko C, Paletta B, Reschenhofer E, Ott E: Nicotnamide adenine dinucleotide (NADH) as medication for Parkinson's disease: Experience with 415 patients. Trends Clin Neuropharmacol 4: 7-24, 1990.
97. Birkmayer W, Birkmayer J, Vrecko K, Paletta B: The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in Parkinson's patients. In Strifler M, Korezyn A, Melamed E, Youdin M (eds). “Parkinson's Disease: Anatomy, Pathology, and Therapy.” New York: Raven Press, 545-549, 1990.
98. Vrecko K, Birkmayer J, Krainz J: Stimulation of dopamine biosynthesis in cultured PC-12 pheochromocytoma cells by coenzyme nicotinamide adenine dinucleotide (NADH). J Neurotransmission 5: 147-156, 1993.
99. Prasad K, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson W: Modification of the effect of tamoxifen, cis-platin, DTIC and interferon-a2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 22: 233-245, 1994.
100. Prasad K, Kumar R: Effect of individual antioxidant vitamins alone and in combination on growth and differentiation of human non-tumorigenic and tumorigenic parotid acinar cells in culture. Nutr Cancer 26: 11-19, 1996.
101. Brumas V, Hacht B, Filella M, Berthon G: Can N-acetyl-Lcysteine affect zinc metabolism when used as a paracetamol antidote? Agents & Actions 36: 278-288, 1992.
102. Hjortso E, Fomsgaard JS, Fogh-Andersen N: Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally? Eur J Clin Pharmacol 39: 29-31, 1990.